Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer

RATIONALE: This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC). Bevacizumab was later in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Messersmith, Wells A., Jimeno, Antonio, Jacene, Heather, Zhao, Ming, Kulesza, Piotr, Laheru, Daniel A., Kahn, Yasmin, Spira, Alexander, Dancey, Janet, Iacobuzio-Donahue, Christine, Donehower, Ross C., Carducci, Michael, Rudek, Michelle A., Hidalgo, Manuel
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033228/
https://ncbi.nlm.nih.gov/pubmed/21208844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CCC.2010.n.043
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares